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Abstract Antibiotic resistance in systemic infection is well-
researched and well-publicized. Much less information is
available on the resistance of normal ocular microbiome and
that of ophthalmic infections. An understanding of the distri-
bution of ocular microorganisms may help us in tailoring our
empiric treatment, as well as in choosing effective pre-, peri-
and postoperative management, to achieve the best results for
patients. This study aims to summarize and review the avail-
able literature on the subject of normal ocular flora and its
resistance, as well as the broader topic of antibiotic resistance
in ophthalmology.
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Introduction
Ophthalmic infections vary greatly in severity. Bacterial con-
junctivitis is probably the most common ophthalmic infection,
often seen by primary care physicians, and is self-limiting and
not sight-threatening [1]. On the other end of the severity
spectrum, endophthalmitis is a rare yet extremely serious
infectious complication of ocular surgery, particularly cataract
surgery, ocular trauma or intravitreal injections [2].
The drug arsenal available to ophthalmologists is expected
to expand continuously with the introduction of new and more
effective drugs. However, this is not true in the case of antibi-
otics, as resistance is expected to pose an increasing threat to
effective treatment of ocular infections [3].
The globe of the eye is well protected from exogenous
microorganisms under normal conditions. However, penetrat-
ing trauma—be it random, surgical or associated with injec-
tion—can facilitate the migration of elements of the ocular
flora into the eye, resulting in infection [4].
Although endophthalmitis is considered a very rare com-
plication, with estimated occurrence at approximately 0.03–
0.2% after cataract surgery and 0.02–0.2% after a single intra-
vitreal injection, the high volume of cataract surgery per-
formed worldwide results in thousands of cases of endoph-
thalmitis each year [5, 6]. Furthermore, poor outcomes of
acute endophthalmitis cause significant morbidity and vision
loss globally.
The devastating effects of endophthalmitis have caused
many ophthalmic surgeons to use pre- or perioperative topical
antimicrobial prophylaxis. In a 2001 survey regarding antibi-
otic use conducted by the American Society of Cataract and
Refractive Surgery, 96% of the 1300 surgeons surveyed used
perioperative topical antibiotics. This remains largely un-
changed today, with the more recent 2014 survey showing
90% of surgeons using perioperative antibiotics and 85%
using preoperative antimicrobials [7, 8]. The choice of peri-
operative antibiotic depends on a multitude of factors, with
major considerations including the spectrum of action, time
required to eliminate bacterial flora from conjunctival surface,
cost and resistance patterns [2, 3].
Identifying patients at higher risk of postoperative endoph-
thalmitis is also important in reducing the risk of
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endophthalmitis [9]. Up to 82% of post-cataract endophthal-
mitis may be caused by ocular flora [10], underscoring the
need to understand and monitor the distribution of ocular mi-
croorganisms and infections and their antibiotic resistance in
order to best tailor pre-, peri- and postoperative management..
Ocular bacterial flora
Normal ocular flora is diverse. Individual microorganisms
within the ocular flora interact with each other as well as with
defense mechanisms of the eye and immune system [4]. Tears
function as one such antimicrobial defense—they contain the
antimicrobial enzyme lysozyme, and also act together with the
mechanical action of the eyelids in washing away pathogens.
Under normal conditions, this results in a balance preventing
the overgrowth of a particular microorganism and therefore
infection [4].
Using conventional culture techniques—chocolate
agar or blood agar plate, broth culture—75–82% of con-
junctival cultures have been found to be positive for at
least one organism [3, 11, 12].
One of the most common bacteria found on the surface of
the eye is coagulase-negative staphylococci (CoNS). These
are assumed to be commensal bacteria, colonizing the mucosa
and lid margins [11]. CoNS are the most commonly found
bacteria, detected in up to 100% of positive conjunctival cul-
tures taken from patients preoperatively, with Staphylococcus
epidermis the predominant species [3, 11, 13]. This has been
extensively corroborated in studies from as early as 1954 [14,
15], and appears to be true around the world, with studies in
Japan, Korea, the USA, Finland, Uganda and even rural pop-
ulations of Sierra Leone [3, 11, 13, 16–20].
Some of the commensal organisms commonly constituting
ocular flora are Staphylococcus aureus, Propionibacterium,
Corynebacterium , Pseudomonas aeruginosa and
Haemophilus influenzae [3, 11, 13]. Studies employing non-
cultivable molecular techniques for determining ocular
microbiome have only recently emerged [21]. In a study com-
paring results from conventional culture techniques and 16S
RNA sequencing (a gene sequencing technique used for iden-
tifying strands of bacteria in a sample), a much wider range of
microbial organisms was identified using the latter, with
Rhodococcus sp., Klebsiella sp., Propionibacterium sp. and
Erwinia sp. isolated [11].
Studies have attempted to identify patterns with re-
gard to ocular flora, particularly the distribution of re-
sistant organisms among studied populations. Research
into factors affecting ocular flora may help in identify-
ing at-risk groups and providing guidance for future
prophylactic and treatment guidelines.
A high prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) has long been observed in healthcare workers
[22]. However, one study investigatingMRSA colonization in
non-operative eyes of 399 pre-cataract surgery patients found
that being a healthcare worker or family member of one did
not confer additional risk of being colonized by a methicillin-
resistant organism (P = 0.54, P = 0.26) [19]. This conclusion
was supported by another study [23].
Researchers have reported that older patients are more likely
to haveMRSA or methicillin resistant CoNS, particularly those
over 80 years of age, with methicillin-resistant (MR) organisms
found in 29.5%, 33.3%, 34.0%, 48.3% and 50% of patients
aged 50–59, 60–69, 70–79, 80–89 and 90–99 years, respective-
ly [19]. Similar MR isolation rates have been found in patients
older than 60 [13], but this correlation has not been universally
reproduced, with a 2015 study of 183 preoperative eyes finding
no statistically significant relation between age and colonization
of MR organisms in ocular flora (P = 0.06) [23].
Two prospective studies in Japan both found that bac-
terial isolation rates were significantly lower in patients
using eye drops. In one investigation of 579 eyes, the
positive culture rate was 46.7% (n = 304) in patients not
using eye drops and 30.9% (n = 275) in the comparative
group using eye drops. Similar culture rates were ob-
served in patients suffering from dry eye syndrome and
actively using eye drops: 19.8% (n = 96), compared to
43.1% in those that did not (n = 483) [13]. A second study
reported an isolation rate of 40.3% (n = 119, P < 0.001) in
patients using glaucoma eye drops, versus 67.8% (n = 28,
P < 0.05) in the control group not using eye drops [17].
The authors of these two studies hypothesized that these
observations might be due to a washout effect following
instillation of eye drops [13, 17].
Data are conflicting regarding the influence of diabetes
on ocular flora. The first of the aforementioned Japanese
studies found no significant difference in the bacterial
detection rate in relation to diabetes status, haemoglobin
A1C levels, diabetic retinopathy or glycosuria [13].
However, the study did find higher rates of methicillin
resistance in patients with diabetes mellitus [13].
Similarly, a study in Turkey, designed specifically to
study differences in bacteria cultured from diabetic and
non-diabetic patients, found no difference in culture rates
between the two groups, but did find a statistically signif-
icant (P = 0.018) higher rate of gram-negative organisms
cultured from diabetic patients [24]. Furthermore, an in-
vestigation into the ocular flora of diabetic patients with
normal and altered HbA1c levels found no difference be-
tween the two groups [25]. In contrast, a US based study
from 2010, previously referenced for the data on MRSA
colonization in healthcare workers, found diabetic patients
to be less likely to be colonized by MR organisms
(P = 0.02) [19]. A 2014 study based in Bangladesh
showed 64% and 38% culture-positive rates for diabetic
(n = 50) and non-diabetic (n = 250) patients respectively,
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with an additional trend of higher rates of S. aureus iso-
lation in diabetic patients [26].
Another factor postulated to influence ocular flora is
geographical distribution [27]. The difference in eye flora
and resistance patterns in relation to geography was de-
scribed as early as 1954 when results from eye cultures
from two London based eye hospitals differed [14]. This
is supported by a unique study of 4432 patients undergo-
ing cataract surgery between 1994 and 1996 in Madrid,
which showed significant differences in ocular surface
flora that correlated to seasonal climate changes in the
area [28]. The authors found that in warm, humid
months—April, May and June—the overall positive bac-
terial rate increased. A seasonal effect was also observed
with S. pneumoniae, with isolation rates rising in March,
November and December, and with Haemophilus sp.,
with isolation rates rising in January and April [28].
Furthermore, the authors found that the rates of rehospi-
talization for post-cataract extraction endophthalmitis
were 3.37 times as high as those in May and June, but
no statistical analysis could be performed due to a variety
of confounding factors and low numbers of endophthal-
mitis patients overall [28].
To the best of the authors’ knowledge, no published
studies have investigated geographical differences in ocu-
lar surface microbial flora between countries. Table 1 pre-
sents results from a number of studies looking into normal
bacterial flora from different geographical areas.
Other factors that have been found to correlate with
changes in the composition of ocular surface flora in-
clude alcoholism (significantly higher incidence of
S. aureus found in subjects with chronic alcoholism
compared to the healthy population) [29], Behçet’s dis-
ease (significantly higher rates of colonization with
S. aureus, Moraxella sp. and Streptococcus sp. in
Behçet’s patients) [30], and hyperlipidemia (lower bac-
terial detection rate, possibly due to changes in
nasolacrimal duct fluid) [13].
Factors that have been investigated and found to have no
effect on the composition of ocular microbial flora include
AIDS and immunosuppression [31], pregnancy and reproductive
status (women of reproductive age vs. postmenopausal) [32], and
recent hospitalization. A summary of results from studies focus-
ing on factors affecting ocular microbiome is shown in Table 2.
Analysis onmice suggests that ocular flora may be required
for mounting a sufficient immune response to ocular infection
later in life [36]. Commensal flora may thus have a more
complicated role to play regarding ocular surface health and
immunity. Research into the way ocular microbiome influ-
ences both innate and adaptive immunity is sparse; however,
data signifying its importance continue to accumulate [37].
This is further discussed in a literature review by Kugadas
et al. [37].
Antibiotic resistance in ocular microorganisms
The development of bacterial resistance in vitro was demon-
strated as early as the 1940s [33]. Since then, resistance to
antimicrobial agents continues to emerge worldwide, with
multidrug-resistant organisms becoming increasingly com-
mon. The mechanisms by which bacteria develop antibiotic
resistance at the cellular level are mutations and genetic ex-
change [34]. The effects of those are further multiplied by the
selective pressures in health care and community. The extend-
ed use of antimicrobials not only in hospitals, but also in long-
term or day care facilities, outpatient settings, industrial live-
stock production and veterinary care, all promote the devel-
opment and survival of resistant bacterial strains [34].
Infections caused by antimicrobial-resistant strains may not
only be more difficult to treat, but can also cause increased
morbidity. An experimental study on rabbits found endoph-
thalmitis caused by resistant S. epidermidis caused more in-
flammation and ocular tissue destruction than non-resistant
strains [35].
Emergence and progression of resistance on a regional,
national, and worldwide scale has been widely studied and
is almost universally accepted. As listed above there is a mul-
titude of factors influencing development of resistance. In
view of the multifactorial nature of antibiotic resistance, a very
important question, in terms of shaping future practice, is
whether we as ophthalmologists can influence the resistance
patterns of our patients with our daily practice. At least two
studies have demonstrated that use of prophylactic antibiotics
in the setting of intravitreal injections causes a statistically
significant rise in ocular colonization with resistant strains
[38–40].
In a study by Milder et al., 80 eyes from 40 patients who
had previously received at least three injections for exudative
AMD in one eye only were selected, the other eyes serving as
controls. Patients had received seven injections on average
(range 3–13) in the study eye, and were given a single drop
of fluoroquinolone and either polymyxin B/trimethoprim eye
drops (n = 29) or fluoroquinolone eye drops (n = 11) for 4 days
afterwards [40]. The rate of resistance to fluoroquinolones was
almost double the resistance in the controls (63.6% vs 32.1%,
p = 0.04). Furthermore, among eyes treated with a 4-day post-
injection course of fluoroquinolone, resistance was 87.5%
(n = 8), compared with 25% in the matched untreated eyes
(p = 0.04) [40]. No difference in trimethoprim resistance was
found.
In a prospective randomize, longitudinal study by Kim and
Toma, 48 eyes from 24 patients undergoing unilateral intravit-
real injections were selected, with contralateral eyes not re-
ceiving injections serving as matched controls [41]. These
patients were then randomized to the use of either ofloxacin,
gatifloxacin, moxifloxacin or azithromycin (8 patients in each
group), and using only their assigned antibiotic after each
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injection. Injections were administered 4 weeks apart, and
patients were instructed to use their antibiotic for 4 days
after the injection, 4 times a day for fluoroquinolones and
2 times a day for azithromycin. Baseline resistance of
CoNS to erythromycin and azithromycin was 57% and
65%, respectively, and resistance to fluoroquinolones
ranged from 34 to 39% for moxifloxacin and gatifloxacin,
and from 57% to 52% for ofloxacin and levofloxacin [41].
A total of 70 CoNS isolates were identified from control
eyes; those did not demonstrate a significant increase in
rates of resistance to fluoroquinolones or macrolides over
the study period. In eyes treated with fluoroquinolones, 48
CoNS cultures were grown (visits 1–4), and showed
ofloxacin and levofloxacin resistance of roughly 85%
(p = 0.003) , and res i s tance to ga t i f loxac in and
moxifloxacin approaching 67% (p = 0.009) and 77%
(p < 0.001), respectively [41]. A similar trend was found
in eyes treated with azithromycin, with resistance to
ma c r o l i d e s o f 9 4% ( p = 0 . 0 0 9 , c omp a r e d t o
fluoroquinolone-treated eyes), along with decreased levels
of resistance to fluoroquinolones [41].
Finally, Hsu et al. studied changes in conjunctival flora and
resistance patterns in patients undergoing intravitreal injec-
tions without post-injection antibiotics, relying on povidone-
iodine antisepsis only. The study concluded that no significant
changes to ocular flora or resistance patterns occurred in stud-
ied subjects [42]. This further supports that the causative fac-
tor in two previously described studies is most likely antibiotic
use. The three above aforementioned studies interpreted col-
lectively suggest that antibiotic use may have a measurable
and immediate influence in the emergence of resistant bacte-
rial strains in our patients.
In response to a perceived threat from increasing antibiotic
resistance worldwide, the World Health Organization, the
United States Food and Drug Administration, and other large
organizations started surveillance programs amalgamating da-
ta from the USA and worldwide [43–45].
Two such initiatives are of particular interest to ophthal-
mology—Ocular Tracking Resistance in the U.S. Today
(TRUST) and Antibiotic Resistance Monitoring in Ocular
Microorganisms (ARMOR) [43, 44, 46].
TRUST is a nationwide US-based multicenter surveillance
program established in 1996, in which isolates are sent from
over 200 clinical laboratories to an independent central labo-
ratory for in vitro susceptibility testing. An ocular-specific
substudy was initiated in 2005 (Ocular TRUST1) looking to
gather prospective data each year as well as to retrospectively
analyze ophthalmic samples from previous years [44, 46]. The
TRUST study looks specifically at three microorganisms—
Staphylococcus aureus, Streptococcus pneumoniae,
Haemophilus influenzae. S. aureus being further divided as
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The ARMOR study is a similar surveillance program set up
specifically to monitor ocular pathogens across the United
States. Initial results from the ARMOR study based on iso-
lates collected from 34 institutions over the course of 2009
were published in 2011 (ARMOR 2009), and subsequent data
from 2009 through 2013 (ARMOR 2013) were published this
year. The ARMOR study extends data collected for TRUST
studies with analysis of Pseudomonas aeruginosa and CoNS.
The ARMOR 2013 study analyzed a total of 3237 isolates and
is the largest study of its kind to date.
Table 3 provides a summary of the resistance levels found
in the TRUST and ARMOR studies.
Difficulties in assessing resistance in ophthalmology
Studies regarding antibiotic resistance in ophthalmological
practice have often been confounded by small case numbers
[44]. This is especially apparent in the specific case of micro-
biological isolates from cases of endophthalmitis, as the low
incidence rate implies that single-center studies are unlikely to
gather sufficient data for results to be statistically significant
[43, 44]. Although the Ocular TRUST and ARMOR 2009
studies included a large number of prospectively gathered
isolates, it was not until the ARMOR 2013 results were pub-
lished that trends in resistance could be statistically analyzed.
Another limitation of published studies lies in the way bac-
terial susceptibility is detected. Determination of bacterial re-
sistance is based on minimum inhibitory concentrations
(MICs), the lowest concentration of an antimicrobial that will
inhibit growth of a given microorganism. The MICs used in
most studies are based on systemic drug administration, and
subsequently on the average concentrations of the drug in
tissues [3, 13, 43, 44, 46]. This is not necessarily representa-
tive of antimicrobial therapy used in the treatment of patients.
For example, topical application of antimicrobials, as com-
monly used in ophthalmological practice is likely to provide
higher drug exposure over time than systemic use [44]. As
noted in Ocular TRUST1, one study looking into pharmaco-
kinetics of 0.5% levofloxacin ophthalmic solution found that
the area under the curve (AUC, a measure of drug exposure
time) over 6 h was more than twice that with oral or intrave-
nous dose of 750 mg levofloxacin over 24 h [44, 47]. Similar
findings have been reported for azithromycin with application
of 0.5%, 1% or 1.5% azithromycin topical solution, resulting
in tear film AUC0-24 (a measure of drug exposure over 24 h)
of between 108 and 362, two orders of magnitude higher than
standard oral 3- or 5-day regimens or single-dose extended
release (AUC0-24 of 2.58, 2.60, and 8.62), respectively [48,
49]. The effect of higher antibiotic concentration with topical
application maymean that thresholds set for resistance in large
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Institute (CLSI) or automatic microbial equipment underesti-
mate antimicrobial sensitivity in ocular pathogens.
One more difficulty with correlating laboratory data with
clinical effectiveness arises from difficulties in obtaining data
regarding penetration of topical antibiotics into deeper struc-
tures of the eye and subsequently their concentrations over
time. Antibiotic penetration may be another factor influencing
clinical success rates, but there are limited data on this subject.
One study found that topical moxifloxacin and gatifloxacin
penetrated the anterior chamber to a greater degree than cip-
rofloxacin, achieving much higher concentrations [50].
Another issue that makes accurate assessment of re-
sistance difficult is the lack of a standardized framework
for studying ocular pathogens and the different interpre-
tive criteria for susceptibility. Although some, like the
aforementioned trials, used CLSI-defined breakpoints [3,
13, 43, 44, 46], others used automatic microbial systems
[51], and some studies reported the method of testing or
the laboratory that performed it but not the framework
adhered to or thresholds that were chosen [19, 52].
A potential weakness present in both Ocular TRUST1 and
ARMOR is selection bias. The methodology for both studies
is based on analyzing samples of already cultured organisms
[44, 46]. However, culturing in ophthalmology is relatively
infrequent, and although treatment guidelines for many types
of ophthalmic infections state that culture should be taken
prior to commencement of antibiotic therapy, clinicians will
sometimes start empiric therapy and take cultures only if the
therapy fails [2]. Additionally, cultures are more likely to be
taken if the severity of infection is greater. Overall, this might
skew the results towards representing more severe and poten-
tially more resistant infections. Finally, both studies focused
solely onmicrobial isolates of pre-defined taxonomy, omitting
a spectrum of antibiotic resistance in other pathogenic
bacteria.
Resistance levels in TRUST and ARMOR studies
Staphylococcus pneumoniae
Retrospective analysis of 760 S. pneumoniae archived sam-
ples gathered between 1999 and 2006 in the TRUSTstudy has
shown 34.1% of S. pneumoniae to be penicillin-resistant, with
nearly three-quarters of those being cross-resistant to
azithromycin and trimethoprim [44]. The data gathered pro-
spectively by the Ocular TRUST1 study between 2005 and
2006 revealed 9 of 49 (18.3%) S. pneumoniae isolates to be
resistant to penicillin, with all of those also resistant to trimeth-
oprim, azithromycin and tobramycin [44]. Only a single iso-
late of the 760 was resistant to third- and fourth-generation
fluoroquinolones (levofloxacin, moxifloxacin, gatifloxacin).
Ciprofloxacin resistance was 9.7%. There were no statistically
significant changes to S. pneumoniae fluoroquinolone suscep-
tibility over the 8 years of the study [44].
ARMOR 2013 further corroborates these data, with peni-
cillin resistance at 31.8%, azithromycin resistance at 38.4%,
and only single isolates resistant against any generation of
fluoroquinolones [46].
Pseudomonas aeruginosa
Resistance rates among P. aeruginosa samples were low
against all antibiotics tested in ARMOR 2013. With the ex-
ception of polymyxin B, susceptibility was above 90%.
Haemophilus influenzae
Of the 356 H. influenzae isolates gathered in the retrospective
arm of Ocular TRUST1 (1999–2006), 37.4% were β-
lactamase-positive. However, all H. influenzae samples were
susceptible to penicillin and all other antibiotics tested, with
the exception of 14.3% resistance to trimethoprim [44]. In the
prospective portion of Ocular TRUST1, β-lactamase-
producing isolates accounted for 44% of samples (14 of 32);
this had no impact on antibiotic resistance [44]. The ARMOR
study has further supported those findings, showing all but
two isolates to be susceptible to all antibiotics tested in 2009
(n = 73) and in the following 4 years (n = 284), the two excep-
tions being a single isolate resistant to chloramphenicol and
another to chloramphenicol. Neither β-lactamase production
nor trimethoprim susceptibility was tested [43, 46].
Coagulase-negative staphylococci and Staphylococcus
aureus
The prospective arm of Ocular TRUST1 shows 83.2% of
S. aureus isolates to be methicillin-susceptible. Most MSSA
isolates were found to be susceptible to fluoroquinolones, with
less than 20% resistance for any of the fluoroquinolones tested
[44]. This is contrasted by the 75–85% resistance against
fluoroquinolones tested in MRSA isolates. The only agent
consistently active against both MSSA and MRSA was tri-
methoprim, showing only 6.4% resistance in MRSA and
2.4% in MSSA [44]. The data from the ARMOR 2009 study
showed 39% of S. aureus isolates to be methicillin-resistant,
compared to the 16.8% from Ocular TRUST1 isolates gath-
ered in 2006 [43, 44]. Similar to the results found in Ocular
TRUST1, MRSA isolates were found to be multi-resistant,
with 79.5% resistance to ciprofloxacin, 65.4% resistance to
moxifloxacin, and 52.6% resistance to tobramycin [43].
Although MRSA resistance to fluoroquinolones did not in-
crease between the two studies, the doubling of MRSA inci-
dence among S. aureus isolates may mean that ocular infec-
tions caused by S. aureus are twice as likely to be caused by a
methicillin-resistant—and possibly multi-resistant—
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pathogen. In the ARMOR 2009 study, 11.5% of S. aureus
isolates were not susceptible to five different drug classes
[43]. In the ARMOR 2013 study, 86.8% and 77.3% of
MRSA and methicillin-resistant CoNS, respectively, were
found to be resistant to three or more drug classes.
Among CoNS isolated in ARMOR 2013, the vast majority
consisted of S. epidermis (75.9%), perhaps reflecting how
commonly this species forms part of the commensal flora
[46]. The resistance rates from the ARMOR 2013 study
showed that the CoNS resistance profile follows trends similar
to S. aureus, with resistance rates of 49.7% to methicillin
(42.2% for S. aureus), 34.4% to ciprofloxacin (39.8% for
S. aureus), and 61.3% to azithromycin (63.6% for
S. aureus). Perhaps surprisingly, no statistically significant rise
in CoNS or S. aureus resistance was detected during the 5-
year surveillance period of the ARMOR 2013 study [46].
The latest preliminary reports from the ARMOR study for
2014 and 2015 show that high levels of resistance in ophthal-
mology, including multi-drug resistance, continue to be a re-
ality and a challenge today [53].
Preventing the spread of resistance in ophthalmology
Subtherapeutic dosage
A key facet of antimicrobial prescribing is ensuring that we
use antimicrobials in the correct dosage and for the proper
length of treatment. Using too low a dose—so called subther-
apeutic dosage—can accelerate the development of drug re-
sistance: it exposes the microbes to the drug without killing
them, allowing them to develop resistance, multiply and
spread. Similarly, resistance can be promoted with antimicro-
bial treatment duration that is too short. Incorrect dosages for
antimicrobials are surprisingly common, especially for chil-
dren, as many drugs are not available in pediatric dosages. A
study in 2015 showed that nearly half the children in the
sample were treated with suboptimal dosages of commonly
used antifungal agents [54]. A possible driver of this routine
non-optimal dosing is the lack of recent studies on the phar-
macokinetics (PK) and pharmacodynamics (PD) of antibi-
otics. Additional studies would enable a better understanding
of how the drug is broken down, absorbed, and excreted. This
is crucial for determining optimal dosing regimens. Many PK
and PD studies on antibiotics were conducted in the 1950s and
1960s, when these antibiotics were first discovered. Now, with
improved techniques and protocols for PK/PD studies, these
antibiotics must be re-evaluated to ensure that they are being
used in the most efficient way possible. Many of the antibi-
otics used in ophthalmology in particular are topical or
intracameral, and thus most of the studies regarding systemic
administration PK/PD parameters may not be applicable—
and may even be misleading.
Using the right antibiotic
In an ideal world, prescribing of an antibiotic would occur
only after identification of the pathogen, along with resistance
testing, in order to ensure the choice of the best-suited antimi-
crobial. In real world practice this is not always practical or
even possible, so antibiotics are often prescribed empirically.
One of the key issues with conventional culture and disk dif-
fusion or broth dilution resistance testing is the relatively long
time before the pathogen is identified (24–48 h), and another
24 h to complete susceptibility testing [55]. By the time a
clinician receives the full culture report, the response to the
antibiotic, started 48–72 h earlier, can often be judged empir-
ically by examining the patient. To address this problem, a
number of rapid diagnostic tests are being developed and
employed [55]. These include many polymerase chain reac-
tion (PCR) and peptide nucleic acid fluorescence in situ hy-
bridization (PNA-FISH) tests from various manufacturers
[55]. Both of these tests work by identifying known resistance
or species-specific coding sequences. The PCR method am-
plifies the sought-after sequence, making it detectable by other
methods such as electrophoresis, while PNA-FISH uses fluo-
rescence for detection. Results from these tests are available
within 45 min to 6 h [55]. Another emerging method for rapid
susceptibility testing is bacterial cytological profiling (BCP).
BCP relies on identifying key changes in pathogens exposed
to a particular antibiotic by assessing individual cytological
parameters of hundreds of cells using automated systems [56].
The cultured pathogens are treated with an antimicrobial, and
the response in terms of cell and nucleus size, shape and vol-
ume is assessed under fluorescence-basedmicroscopy for spe-
cific changes indicating susceptibility or resistance [56]. It is
important to note that neither of these methods is being devel-
oped with ophthalmology in mind, aiming instead at aiding in
the diagnosis of systemic infections. Thus they would need to
be adapted for ophthalmic use. In the future, these innovations
may help ophthalmologists in choosing the right antimicrobial
and reserving antibiotics of last resort, while remaining confi-
dent in the therapeutic effect of the antibiotic prescribed.
Using antibiotics only when proven to provide a tangible
benefit
An indispensable message in every antibiotic stewardship pro-
gram is the importance of using antibiotics only when neces-
sary [57]. The case of antimicrobial prophylaxis in the setting
of IVI is a prime example where research has shown that
alternative infection control methods are at least as effective
[6]. An additional benefit in not using antibiotic prophylaxis
in IVI is an estimated annual savings of $300 million in the
USA, compared to using antibiotic prophylaxis for every IVI
[58]. A second area where a large-scale change in practice
may be possible is the use of topical antibiotics prior to
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cataract surgery. A recent review of the literature concluded
that, despite the widespread practice, the evidence supporting
preoperative topical antibiotics is not compelling [59]. Finally,
antibiotics are often misused in the treatment of viral and
allergic conjunctivitis [58]. Studies show that up to 80% of
conjunctivitis cases are of viral origin, which do not require
treatment with antibiotics and are usually self-limiting [60].
Moreover, topical antibiotics are contraindicated, as they do
not protect against secondary infections, and may blur the
clinical presentation by causing toxicity or allergic reactions
[60]. This is a problem that has been highlighted in the past,
with the American Academy of Ophthalmology designating
antibiotic use in the setting of IVI and viral conjunctivitis as
two of the top five unnecessary interventions in ophthalmol-
ogy [58].
Alternatives to antibiotics
Previously there were hopes that the newer-generation
fluoroquinolones might help stop the spread of resistance
[2]. Today, with reports of resistance levels to those antibiotics
as high as 70%, this hope appears unfulfilled [38]. There are,
however, important alternatives to antibiotics that are applica-
ble in many situations. A recent review of upcoming antibiotic
substitutes or adjuncts highlighted 10 key emerging ap-
proaches, including immune stimulation, probiotics, lysins,
bacteriophages and antimicrobials peptides [61]. Although
this review was focused on systemic therapy, antimicrobial
peptides were identified as having considerable potential for
topical therapy [61].
One such alternative already employed in ophthalmology
is the use of effective antiseptics, as illustrated in the case of
IVI. In recent years, large-scale research has demonstrated the
safety of using povidone-iodine 5% solution in preventing
IVI-associated endophthalmitis [62]. A recent survey of
American retina specialists has shown that 89% do not use
any antibiotics in IVI, and another 5% use them only in select
patients, reflecting major antibiotic-sparing initiatives in oph-
thalmology are still very much possible in this day and age
[63]. The hope is that, with current and future reports coming
from the USA of good outcomes without the use of antibi-
otics, the rest of the world will gradually adopt an IVI practice
based on good aseptic techniques, thereby minimizing the use
of topical antibiotics and reducing the rise of antimicrobial
resistance.
Antiseptics have become a mainstay in postoperative en-
dophthalmitis prevention. Povidone-iodine (PVI) and chlor-
hexidine are the two major antiseptics of choice in ophthal-
mology. PVI solutions act by releasing free iodine, which
readily penetrates the microbial membrane, causing
intracytoplasmic oxidation of proteins and cell death as a re-
sult [64]. Chlorhexidine, on the other hand, is a much larger
molecule and cannot penetrate the microbial cell wall—de-
pending on the concentration, it exerts a bacteriostatic effect,
with destruction of cell membranes. At higher concentrations
it shows bactericidal activity by causing leakage, coagulation,
and precipitation of cellular contents [64]. Although both an-
tiseptics offer good activity against a large spectrum of gram-
positive bacteria, PVI has a larger spectrum against other mi-
croorganisms. The spectra of activity of the two antiseptics are
compared in Table 4. Although both PVI and chlorhexidine
can cause hypersensitivity reactions, there have been no re-
ports of anaphylaxis following topical application of PVI [65].
The allergy profile of PVI is considered excellent; adverse
skin reactions to topical PVI are very rare and are overwhelm-
ingly caused by skin irritation rather than allergic immunolog-
ical processes [66]. Immunological reactions to chlorhexidine
are comparatively common, and relatively frequent allergic
contact dermatitis as well as urticarial and anaphylactic reac-
tions have been described [66]. Unfortunately, the phenome-
non of resistance is not limited to antibiotics. Chlorhexidine
resistance has been described, particularly among MRSA and
other staphylococcal infections, with a number of responsible
genes identified [67]. To the best of the authors’ knowledge,
there are no reports to date of PVI resistance. A recent work
showed that PVI 1.25% was an effective alternative to antibi-
otics in treating bacterial keratitis, suggesting that antiseptic
use in ophthalmology may expand beyond prevention [68].
Table 4 Spectra of antimicrobial
activity for povidone-iodine and
chlorhexidine. Adapted from
Lachapelle et al. [64]
Chlorhexidine Povidone-iodine 10%
Gram-positive bacteria Activity High High
Spectrum Large Large
Gram-negative bacteria Activity High High
Spectrum Incomplete Large
Fungi Activity Medium High
Spectrum Incomplete Large
Viruses Activity Low Medium
Spectrum Incomplete Large
Actinobacteria Activity No activity Medium
Spores Activity No activity Medium
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Conclusions
The eye surface is home to a diverse set of organisms. Based
on current information, we have a good understanding of what
microbes normally constitute the ocular biome. Nevertheless,
much remains to be learned regarding factors influencing the
composition, characteristics, resistance and pathogenicity of
ocular flora, in order to effectively combat resistance in oph-
thalmology. The WHO, in its Global Action Plan on
Antimicrobial Resistance, outlines a few strategic objectives
which relate to the current situation in ophthalmology [69].
WHO notes that, in order to fight resistance, important gaps in
knowledge, particularly the B…incidence, prevalence, range
across pathogens and geographical patterns related to antimi-
crobial resistance is needed to be made accessible in a timely
manner….^ More work remains to be done on the geograph-
ical distribution of both normal flora and resistance in normal
flora and infection.
Effective antimicrobials are needed inmany preventive and
curative efforts in ophthalmology. However, distinguishing
which antibiotics should be used in what situations, and where
alternatives to antibiotics are more appropriate, is critical.
Intravitreal injection (IVI) is a prime example where unneces-
sary and/or improper use of antibiotics may have serious
consequences.
Where antibiotics are required, they should be used in ac-
cordance with established microbiological guidelines and
specifications in order to obtain high concentrations in target
tissue and maintain sufficient duration of effects to reduce
resistance. Repeated short-term exposure to topical antibi-
otics, as is seen in the setting of IVI for chronic retinal disease,
can quickly promote an antibiotic-resistant ocular biome. This
is illustrated by reported rates of resistance to moxifloxacin
and gatifloxacin of as high as 70% in patients undergoing IVI
with antibiotic prophylaxis after just 1 year of serial IVI [38].
Equally important, we as clinicians should be aware that
labeling a microorganism as resistant is based on both system-
ic administration of antibiotics and systemic infection.
Concentrations achieved through topical use are often much
higher and may still be effective.
Microbial resistance is an important subject, with much
innovation and research in prevention, detection and treat-
ment of resistant bacteria. Unfortunately, for ophthalmol-
ogists, most of this research is focused on systemic infec-
tion, and it will take some time before diagnostic and
preventive methods are viable in ophthalmology.
Furthermore, many may never be validated for ophthalmic
use. The situation is different with antiseptics—PVI and
chlorhexidine are already used in everyday practice, and
their use may expand to replace antibiotics in procedures
other than IVI. Most importantly, both antiseptics have
key advantages of non-selective mechanisms of action
(preventing the development of resistance) and low cost.
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